Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Valeant (VRX) initiated with a Market Perform at BMO Capital by analyst Gary Nachman, who set a $26 price target on the stock. The analyst also initiated Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Flexion (FLXN) and Neos Therapeutics (NEOS) with Outperform ratings and Endo (ENDP), Impax (IPXL) and Amphastar (AMPH) with Market Perform ratings. 2. Regeneron (REGN) initiated with an Outperform rating and $400 target at Bernstein. The firm expects the sales of the company's Praluent drug to accelerate, and it believes that the shares have reached an attractive entry point following their steep decline since 2015. Bernstein also initiated Biogen (BIIB) with an Outperform rating and $282 target. 3. Newfield Exploration (NFX) initiated with a Buy at Canaccord by analyst Stephen Berman, citing its leading position in the Anadarko Basin SCOOP and STACK plays of Oklahoma, solid balance sheet, and cost efficiencies. Canaccord has a $48 price target on Newfield Exploration shares. 4. Fleetmatics (FLTX) initiated with an Overweight at Morgan Stanley by analyst James Faucette, who put a $52 price target on the stock. The analyst said improved commercial vehicle utilization is an underappreciated market opportunity and believes the company is well positioned to expand its value proposition and drive market adoption and up-sell subscriptions. Fleetmatics was also initiated with an Outperform rating and $52 target at Baird. 5. Pure Storage (PSTG) initiated with a Neutral at Baird as they sit on the sidelines waiting for clarity on the company's market share trajectory. Baird has a $12 price target on Pure Storage shares. Pure Storage was also initiated with an Outperform rating and $15 price target at Macquarie by analyst Rajesh Ghai. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Wedbush analyst Laura Chico raised the firm's price target on Biogen to $215 from $213 and keeps a Neutral rating on the shares. It remains early days for newly launching products like Skyclarys, Leqembi and Zurzuvae, the firm notes. That being said, it is encouraging to start to see revenue growth for Leqembi and continued growth for Skyclarys. Wedbush continues to see a gap between the newly launching products and earlier-stage development programs that will need to be addressed. However, larger-scale BD deals are likely easier to complete in 2025.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here